The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time

Thrombosis and Haemostasis

Volumn 98, Issue 2, 2007, Pages 397-405

  Wadanoli, Michael ^a   Sako, Dianne ^a   Shaw, Gray D ^a   Schaub, Robert G ^a   Wang, Qin ^a   Tchernychev, Boris ^a   Xu, Jin ^a   Porter, Thomas J ^a   Huang, Qinheng ^a  

^a PFIZER INC   (United States)

Author keywords

DDAVP; Glycoprotein (GP) Ib ; Platelet adhesion activation; Thrombosis; vonWillebrand factor

Indexed keywords

ADENOSINE DIPHOSPHATE; CHIMERIC PROTEIN; COLLAGEN; DESMOPRESSIN ACETATE; GLYCOPROTEIN IB ALPHA; GPG 290; RECOMBINANT PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; EX VIVO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANIMALS; BLEEDING TIME; CORONARY THROMBOSIS; DEAMINO ARGININE VASOPRESSIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE PROTEINS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; RECOMBINANT FUSION PROTEINS; VON WILLEBRAND FACTOR;

EID: 34547862097     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0582     Document Type: Article

References (30)

1. McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003; 93: 381-396.
2. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
3. Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther 2003; 1: 257-269.
4. Penz SM, Reininger AJ, Toth O, et al. Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaues. Thromb Haemost 2007; 97: 435-443.
5. Pontiggia L, Steiner B, Ulrichts, et al. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIbα. Thromb Haemost 2006; 96: 774-780.
6. Andrews RK, López JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29: 91-105.
7. Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coag Fibrinol 1994; 5: 97-119.
8. Huizinga EG, Tsuji S, Romijn RAP, et al. Structures of GPIbα and its complex with the vWF-Al-domain. Science 2002; 297: 1176-1179.
9. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2004; 1: 1602-1612.
10. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
11. Hennan JK, Swillo RE, Morgan GA, et al.. Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis. Thromb Haemost 2006; 95: 469-475.
12. Mannucci PM. Management of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 602-609.
13. Folts JD, Edward B, Crowell J, et al. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
14. Krizek Dr, Rick KM. A rapid method to visualize von Willebrand factor multimers by using gel electrophoresis, immunolocalization and luminographic detection. Thromb Res 2000; 97: 457-462.
15. Schaub RG, Rawlings CA, Keith JC Jr. Platelet adhesion and myointimal proliferation in canine pulmonary arteries. Am J Pathol 1981; 104: 13-22.
16. Ikeda H, Koga Y, Kuwano K, et al. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans. J Am Coll Cardiol 1993; 21: 1008-1017.
17. Willerson JT, Yao SK, McNatt J, et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991; 88: 10624-10628.
18. McGhie AI, McNatt J, Ezov N, et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation 1994; 90: 2976-2981.
19. Kageyama S, Yamamoto H, Nagano M, et al. Antithrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol 1997; 122: 165-171.
20. Kageyama S, Yamamoto H, Nakazawa H, et al. Antihuman vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395-404.
21. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-149.
22. Andrews RK, Shen Y, Gardiner EE, et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82: 357-364.
23. Wang Q, Shaw G, Shorten D, et al. The effect of von Willebrand factor on the disposition of GPIbα-Ig in lab animals. AAPS PharmSci 2003, 5: R6182, Abstract.
24. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
25. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
26. Watala C, Golanski J, Rozalski M, et al. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb Res 2003; 109: 299-306.
27. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Hemost 2003; 1: 682-689.
28. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997; 90: 2515-2521.
29. Bernat A, Hoffmann P, Dumas A, et al. V2 reveptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597-602.
30. Vilhardt H, Barth T. The release of factor VIII and tissue plasminogen activator cannot be blocked by specific antagonists to vasopressin. J Recept Res 1991; 11: 239-245.